Led by Chief Executive Officer and Chief Scientific Officer Michael Mullan, M.B.B.S., Ph.D. and Chief Operations Officer and Associate Chief Scientific Officer Fiona Crawford, Ph.D., Archer was created to progress basic research conducted at the not-for-profit Roskamp Institute in Sarasota, Florida, into human clinical trials

Included in this research is clinical development of 新葡萄棋牌平台网站 as a therapeutic for Alzheimer’s Disease. A Phase I/IIA human clinical trial was conducted in Alzheimer’s patients in partnership with the Trinity College Dublin, Ireland. This trial showed that 新葡萄棋牌平台网站 was well-tolerated in Alzheimer’s disease patients, and, together with extensive preclinical data in laboratory models of Alzheimer’s Disease, laid the foundation for a Phase III double-blind, placebo-controlled clinical trial of 新葡萄棋牌平台网站 (the NILVAD study) which was concluded in 2017. Analyses are ongoing and study results are expected to become public in Q1 2018.